|Current issue Archive Manuscripts accepted About the journal Abstracting and indexing Subscription Contact Instructions for authors||
The molecular biology of senile plaques and neurofibrillary tangles in Alzheimer’s disease
Richard A. Armstrong
Folia Neuropathol 2009; 47 (4): 289-299
- 01.pdf [0.23 MB]
Ever since the first descriptions of pre-senile dementia by Alois Alzheimer in 1907 , the formation of senile plaques (SP) and neurofibrillary tangles (NFT) have been regarded as the defining pathological features of Alzheimer’s disease (AD). The Khachaturian  and ‘Consortium to Establish a Registry of Alzheimer’s Disease’ (CERAD)  criteria emphasise the importance of SP in diagnosis, while the NIA-Reagan Institute criteria  suggest both SP and NFT should be considered. Whether SP and NFT are sufficient to cause the neurodegeneration of AD, however, is controversial and has been questioned by a number of authors [8,22,61].
Studies of the molecular biology of SP and NFT have played an important role in the development of hypotheses as to the pathogenesis of AD. For example, the discovery of β-amyloid (Aβ) as the most important molecular constituent of the SP  led ultimately to the ‘Amyloid Cascade Hypothesis’ (ACH), one of the most influential models of the molecular pathology of AD . The ACH proposes that the deposition of Aβ is the initial pathological event in the disease leading to the formation of NFT, cell death, and ultimately dementia. Mutations of the amyloid precursor protein (APP) [28,45] and presenilin (PSEN1/2) genes [63,85], via the generation of pathological Aβ peptides, have been linked to familial forms of AD (FAD). Hence, the presence of Aβ within SP is regarded as the residue of the effect of a pathogenic gene mutation that via the accumulation of toxic and insoluble Aβ peptides leads to cell death. Since the pathological phenotype of familial AD (FAD) is similar, apart from age of onset, to that of sporadic AD (SAD) [13,51,75], studies of gene mutation have had a profound influence on the development of theories as to the pathogenesis of AD in general .
Chemical analysis of SP and NFT in AD reveals them to have a complex and varied composition. There may be at least three types of factor that could influence the molecular biology of SP and NFT (Fig. 1) . First, a molecular constituent could be the residue of a pathogenic gene mutation and therefore be directly related to the primary aetiology. Second, it could be the product of cellular degeneration and therefore, a consequence of the disease process . Third, SP and NFT could acquire new molecular constituents as a result of diffusion and molecular binding to existing proteins [10,15,16]. This review examines the importance of these three factors in determining the molecular composition of SP and NFT in AD and discusses the implications in terms of diagnosis and pathogenesis.
The molecular composition of SP and NFT
SP exist in various morphological forms including diffuse (‘pre-amyloid’), primitive (‘neuritic’), classic (‘dense-cored’), and compact-type (‘burnt-out’) plaques [6,31]. A variety of Aβ peptides are present within these plaques and are formed as a result of secretase cleavage of the transmembrane glycoprotein APP (Table I) . The most common of these peptides is Aβ42/43 found largely in SP, whereas the more soluble Aβ40 is also found in association with blood vessels [67,82] and may develop later in the disease . Diffuse plaques contain Aβ42/43 as well as APP fragments lacking the C-terminus while more mature classic plaques contain Aβ40 in addition to Aβ42/43. Moreover, SP have a variety of ‘secondary’ constituents  including silicon and aluminium , acute-phase proteins such as α-antichymotrypsin and α2-macroglobulin [38,64,99] and their mediator interleukin-6 , intercellular adhesion molecules such as cell adhesion molecule 1 (CAM1) , apolipoprotein E (apo E) which is present in the earliest stages of SP formation  and D (apo D) , the heterodimeric glycoprotein clusterin, vibronectin, the complement proteins C1q, C4 and C3 , blood proteins such as amyloid-P (especially in classic SP), cathepsins B/D , and the sulphated glycosaminoglycans such as heparan sulphate proteoglycan (HSPG). In addition, the prion like protein DOPPEL encoded by the PRND gene may occur in peripheral regions of SP .
The microtubule associated protein (MAP) tau is the most important constituent of the paired helical filaments (PHF) and straight filaments which comprise cellular NFT in AD. There is a single gene for tau and different isoforms result from alternative splicing and post-transcriptional changes . AD is therefore considered to be a tauopathy, a group of disorders that also includes Pick’s disease (PiD), corticobasal degeneration (CBD), the NFT predominant form of senile dementia (NFT-SD), argyrophilic grain disease (AGD), progressive supranuclear palsy (PSP), and parkinsonism-dementia complex of Guam (Guam PDC) [26,34]. The composition of tau differs between the different tauopathies. For example, PiD is characterised by tau with three microtubule repeats (3R tau) while PSP and CBD are composed of four repeat (4R) tau [33,70]. In AD both 3R and 4R tau are present, the 3R/4R tau ratio being highly variable but specific to individual types of neuron . In addition, the molecular composition of the NFT varies markedly depending on whether they are intracellular NFT (I-NFT) or extracellular NFT (E-NFT). Hence, unlike I-NFT, E-NFT are glial fibrillary acidic protein (GFAP) and Aβ immunoreactive , and also contain significant amounts of amyloid-P  and ubiquitin .
The effect of pathogenic gene mutations
The first demonstration of a direct association between a pathological protein and a gene mutation in neurodegenerative disease was made in AD [28,45]. A primary pathogenic role for the APP gene was suggested by the discovery of missense mutations in a small number of families, mutations in exons 16 and 17 being the first established genetic link with FAD . There are three isoforms of APP, viz., APP695, APP751, and APP770, all of which are cell surface glycoproteins with a single membrane-spanning region . Aberrant degradation of APP is believed to result in Aβ formation, especially the peptide Aβ42/43, the major constituent of the SP. APP has a large extracellular N-terminal domain and a short intracellular C-terminal domain while the Aβ sequence itself has 15 amino acids lying within the membrane and 28 extracellular amino acids. The metabolism of APP is mediated by α-, β-, and γ-secretase and in cultured cells that overexpress APP, there are two catabolic pathways. First, the ‘non-amyloid’ pathway in which APP is cleaved within the Aβ sequence by α-secretase and second, the ‘amyloid’ pathway in which APP is cleaved by β- and γ-secretase after endocytosis of the trans-membrane portion . It was originally believed that soluble Aβ was non-toxic but became extremely toxic once fibrils were formed . More recent evidence suggests that Aβ oligomer intermediates are more likely to be the dominant toxic species . Hence, altered proteolytic processing of APP and the accumulation of excess Aβ is assumed to be an early pathological event in FAD, a process which also occurs to a limited extent in aged humans . Following Aβ deposition, the formation of SP, microglial activation, astrocytosis, and neuritic dystrophy presumably lead to the formation of NFT, cell death, and dementia as proposed by the ACH .
Subsequently, the most common subtypes of FAD were linked to mutations of the PSEN [63,85] genes and the effect of these mutations was also assumed to lead, albeit more indirectly, to the enhanced deposition of amyloidogenic species of Aβ . The normal function of the PSEN genes, and how gene mutations result in Aβ deposition in these cases is unclear. PSEN1 may be involved in notch signalling  and may therefore be important in cell differentiation. PSEN1/2 genes may also be implicated via the perturbation of cellular calcium homeostasis  or in interactions with the transcriptional coactivator cAMP-response element binding (CREB-binding) protein which plays a key role in regulating gene expression . In addition, PSEN genes are part of the γ-secretase complex which are important in generating Aβ from APP. Hence, mutant PSEN1 could enhance 42-specific-γ-secretase cleavage of normal APP resulting in increased deposition of Aβ42/43 .
Hence, there is a close relationship between specific gene mutations, amyloid deposition, and FAD. In the case of APP, the product Aβ can be directly related to the gene. In other FAD cases, e.g., those linked to PSEN genes, the connection between the gene mutation and the accumulation of Aβ may be more indirect. These processes, however, account for only a small proportion of cases of AD; the APP and PSEN1/2 genes together accounting for less than 5% of cases . In addition, various questions remain, e.g., if the ACH is correct, how does Aβ lead to the formation of tau , how do Aβ and tau cause cell death in AD, why is the density of lesions so low in some AD cases, and why is the pathology of FAD and SAD so similar?
The effect of structural degeneration within the cell
How do gene mutations result in pathology?
That a more complex relationship may exist between APP mutation, Aβ and AD was first proposed in 1993 . Amino acid changes associated with the codon 717 mutation of the APP gene (APP717) appeared to shed little light on the pathogenic mechanism of AD and existing data from neurotoxicity experiments did not establish a primary role for Aβ in disease pathogenesis . In addition, deposition of Aβ occurs only in areas of cortex with viable neurons, i.e., functional neurons were necessary for the presence of Aβ . Hence, Aβ may not necessarily kill neurons but may be secreted in response to cellular damage. Furthermore, generation of the pathological Aβ sequence requires cleavage by β- and γ-secretase at the N and C-terminal sites [66,103]. As the C-terminal domain lies within the membrane, membrane damage resulting from cellular breakdown, might therefore be a prerequisite for the Aβ fragment to be generated .
Animal models suggest that Aβ peptides may be formed in response to cellular degeneration. Lesions of the nucleus basalis of Meynert (nBM) in the rat, for example, elevate APP synthesis in cortical neurons ; the production of excess APP being a response to loss of functional innervation. Similarly, subacute and prolonged neuronal damage in humans can induce the formation of APP . In the rat, injury to an area of brain results four to seven days later in the presence of APP in axonal swellings, cell bodies, and dystrophic neurites . Lesions of the fimbria-fornix pathway in the rat also result in a marked accumulation of APP in regions of the hippocampus associated with degenerating cholinergic fibres [23,35]. Injections of toxins into the brain produce very similar results, e.g., there are changes in the expression or induction of APP in brain cells after intrathecal or intraparenchymal injections of various toxins  while administration of chloroquine results in the production and accumulation of C-terminal fragments of APP in the cell bodies of pyramidal cells . Furthermore, APP shares structural features with precursors of epidermal growth factor suggesting that APP is an endogenous protectant activated by injury to brain cells . These observations have suggested alternative schemes of pathogenesis in which Aβ is not the primary cause of AD. Hence, theories involving perturbations of vesicular trafficking, the cytoskeletal network, and the distribution of membrane cholesterol are increasingly being explored .
Many other constituents of SP may be a consequence of structural degeneration of the cell. Approximately 40% of diffuse plaques contain degenerating neuronal perikarya [5,7,69] and many contain the processes of astrocytes. Acetylcholinesterase rich neurites have been found in SP and may be the degenerating axonal terminals of neurons originating in the nBM . Cholinergic neurites, and neurites positive for somatostatin, γ-amino butyric acid (GABA), neuropeptide Y , and the catecholamines have all been recorded in SP . As a consequence of neuritic degeneration, PHF antigens, tau, A68 protein, ubiquitin, and NF epitopes are also present . In addition, the presence of neuronal markers such as parvalbumin suggests the preferential incorporation of processes of pyramidal neurons into SP . The presence of chromogranin A, a soluble protein in dense-core synaptic vesicles within the dystrophic neurites of the ‘coronas’ of classic plaques, may also be the result of cellular degeneration [72,80].
The formation of NFT could be a part of the neurons limited response to injury  as neurons will often respond to degeneration by increasing the synthesis of tau . Dopamine denervation and septal lesions affecting cholinergic and GABA neurons projecting to the dentate gyrus result in the loss of dendritic MAP2 and tau immunostaining . Hence, transynaptic changes affecting dentate gyrus neurons may result in the precursor stages of NFT. NFT may also contain additional constituents that result from cellular degeneration  such as NF proteins and synaptophysin .
The effect of secondary acquisition of proteins
Proteins already present within SP and NFT may bind additional molecular constituents, e.g., PHF and amyloid fibres can ‘decorate’ themselves with various proteins [10,102]. In addition, Aβ has a number of trophic properties and can bind metals such as copper, iron, and zinc . Furthermore, during aging, long-lived proteins accumulate post-translational modifications (‘Maillard reaction products’) such as cross-linking, decreased solubility, and increased protease resistance . These changes may alter the chemical composition of a lesion with time and significantly change its binding properties . Electrostatic interactions may also be important in binding exogenous components to Aβ .
Apo E labels a proportion of SP  and is usually detected after the appearance of Aβ  suggesting that it is not a prerequisite for plaque formation even in individuals expressing allele ε4 but is acquired secondarily. Apo E itself can bind to several proteins including Aβ and in the cell targets lipoprotein particles . Several acute-phase proteins and proteins associated with the immune system accumulate in SP. Interleukin-6 is enhanced in both mild and moderate AD, is a mediator of acute-phase proteins, and may be responsible for their accumulation within SP . The membrane attack complex (MAC) has been identified in the dystrophic neurites of SP , and whereas immunoglobulin G (ImG) has not been identified, SP are associated with a variety of complement proteins, CAM, and proteins that may have originated in the blood plasma [11,38]. The presence of C3 and antichymotrypsin suggest that the classic pathway is activated in association with diffuse plaques but it is unclear whether the process proceeds beyond C3. C3 is abundant in serum and therefore, could originate in blood but is also produced by macrophages and astrocytes . Amyloid-P is a complex glycoprotein made in the liver and present in blood serum  and is found in both SP and NFT suggesting that the substance accumulates following impairment of the blood brain barrier [9,36,55]. Approximately 90% of Aβ positive SP contain amyloid-P . The staining pattern of amyloid-P parallels that of the complement proteins suggesting that it may assist microglia during phagocytosis .
SP also contain basic fibroblast growth factor (bFGF), a substance that appears to attract neurites into the plaque . As a consequence, SP acquire various markers associated with the processes of neurons and glial cells. In addition, prion protein (PrP) may accumulate at the periphery of Aβ positive plaques .
The maturation of NFT is associated with several changes in their molecular biology. Hence, E-NFT contain many SP constituents including Aβ, HSPG, amyloid-P, and various serpins [77,78]. I-NFTs are less compact, silver positive, and eosinophilic compared with E-NFT . E-NFTs are also immunoreactive for GFAP and Aβ, both of which are likely to be deposited after cell death. The acquisition of Aβ by E-NFT suggests either that Aβ is inaccessible to I-NFT or that there are conformation changes of the proteins in the extracellular space that facilitate binding of Aβ . A major constituent of NFT is ubiquitin, which is found either as a free molecule or as a protein-ubiquitin conjugate. Ubiquitin may contribute to the polymerization of abnormal fibriller structures in an attempt to eliminate them . As I-NFT develop into E-NFT, they lose the N/C termini of tau and two-thirds of the N-terminus of ubiquitin . NFT are also immunopositive for apo E . In AD, all apo E positive neurons are positive for PHF proteins but not all PHF, tau-2 positive neurons exhibit apo E immunoreactivity . These results suggest that apo E plays a secondary role in NFT formation and is accumulated within neurons in response to repair processes induced by NFT. In the presence of calcium ions, HSPG will bind to the free carboxyl groups of NFT proteins and this binding may play a role in increasing the insolubility of PHF . In addition, bFGF binds to heparinase sensitive sites in NFT due to the presence of HSPG . The MAC has also been identified in association with NFT . Neurons remove membrane inserted MAC fragments by endocytosis and hence, retrograde transport to cell bodies may result in the attachment of MAC to abnormal cytoskeletal proteins such as tau .
What determines the composition of SP and NFT?
The SP and NFT of AD have a rich molecular biology and a summary of the possible origins of their major molecular constituents is shown in Fig 2. The only constituent unequivocally related to a gene product is Aβ, being directly related to mutations of APP. The degree to which Aβ ‘directly’ promotes cell death, however, is more controversial. First, FAD cases are similar, apart from age at onset, to SAD [51,75] and hypotheses such as the ACH do not specify what initiates the common late-onset form of AD . Second, it is difficult to establish a mechanism that directly links a specific APP mutation to cell death.
A variety of mechanisms have been proposed by which abnormal and misfolded proteins may affect cellular homeostasis including disruption of the ubiquitin degradation system, axonal transport, synaptic function, and protein sequestration and these are reviewed in detail by Forman et al. . Third, the presence of Aβ within SP may obscure the primary aetiology because of secondary toxicity effects. Fourth, many of the molecular constituents of SP and NFT may be formed as a response to cellular degeneration including Aβ and tau [14,74,81,101].
SP and NFT also contain several constituents that are directly related to cellular degeneration (Fig. 2). Hence, synaptic disconnection, neuritic degeneration, and invasion by glia add various constituents to developing SP. These processes may explain the presence of tau, PHF antigens, synaptic proteins, and specific neurotransmitter-positive neurites within SP. Subsequently, as lesions age, the activity of some constituents is lost and new compounds acquired. Many of these newly acquired proteins may be made by glial cells or be derived from the bloodstream as a result of breakdown of the blood brain barrier. Hence, GFAP, complement proteins, and acute phase proteins become incorporated into SP. Acquisition of substances by SP as a result of surface diffusion and molecular binding may cause further changes in plaque morphology and alter the properties of the plaque so that it can bind yet further proteins [10,15,16].
Implications for diagnosis
Aβ and tau are currently the most important molecular markers of AD and the various diagnostic criteria emphasise the presence of either SP alone or both SP and NFT in pathological diagnosis [66,68,103]. Nevertheless, the molecular complexity of SP and NFT and the possible origins of the various constituents raise questions about the reliability of using any constituent as the sole pathological marker of disease. First, when many chemical constituents are present, there is the problem of distinguishing the primary ‘pathological’ proteins from reactive products, the breakdown products of the cell, and the compounds acquired by surface diffusion. Studies of FAD have had the most significant influence in identifying the ‘primary’ pathogenic protein, viz., Aβ, the results then being extrapolated to SAD. Aβ, however, may itself be a reaction to cellular degeneration rather than being its cause . Second, the chemical composition of SP and NFT changes as the lesions mature and, in some cases, activity of the primary molecular constituents may be reduced or become substantially altered, and this may cause problems in the diagnosis of AD especially of longer duration cases. Nevertheless, if the value of SP and NFT in the diagnosis of AD is questioned, there is the problem of how AD is to be defined .
Implications for disease pathogenesis
In the conventional view of AD pathogenesis as illustrated by the ACH (Fig. 3A), a causal pathway is hypothesised linking mutations of APP to cell injury and death; the latter mediated presumably by
a variety of changes in cellular homeostasis  and caused by the accumulation of Aβ peptides . This review, however, proposes a more complex interrelationship between these elements (Fig. 3B) in which the primary factor is the age-dependent breakdown of anatomical systems and pathways within the brain and the consequence loss of synapses . The extent of this aging effect, which begins early in life, is mediated by the degree of lifetime stress (the ‘allostatic load’). The brain is the ultimate mediator of stress-related mortality through hormonal changes resulting in hypertension, glucose intolerance, cardiovascular disease, and immunological problems . The consequence is gradual synaptic disconnection, neuronal degeneration, and the upregulation of genes determining various reactive and breakdown products [14,74,81,101]. Second, in small numbers of families, specific APP or PSEN mutations influence the outcome of this age-related degeneration by determining the solubility and/or toxicity of the molecular product. Cells have mechanisms to protect against the accumulation of misfolded and aggregated proteins including the ubiquitin system and the phagosome-lysosome system. Neuronal degeneration in individuals with specific mutations results in the accelerated formation of Aβ and tau, and then a further phase of ‘secondary’ neurodegeneration, which overwhelms the protection systems. Early-onset FAD is the consequence of this process.
By contrast, in individuals without a specific genetic mutation, but where more complex genetic and environmental risk factors are present, the outcome of age-related loss of synapses is mainly soluble and smaller quantities of insoluble proteins which are degraded by the cellular protection systems and do not significantly accumulate to form SP and NFT. With advancing age, however, the protective systems become less effective resulting in slowly accumulating quantities of Aβ and tau. The result of these insidious processes is that the cellular protection systems do not become overwhelmed until much later in life; the consequence being late-onset SAD. The advantage of this modified scheme is that it may explain why the phenotypes of FAD and SAD are similar, why SP and NFT often appear to be distributed independently within the brain, and reflects data suggesting that Aβ and tau are formed as a response to cellular degeneration.
1. Adams LA, Munoz DG. Differential incorporation of processes derived from different classes of neurons into senile plaques in Alzheimer’s disease. Acta Neuropathol 1993; 86: 365-370.
2. Akiyama H, Yamada T, Kawamata T, McGeer PL. Association of amyloid-P component with complement proteins in neurologically diseases brain tissue. Brain Res 1991; 548: 349-352.
3. Alzheimer A. On a peculiar disease of the cerebral cortex.
Allgemeine Zeitschrift für Psychiatrie und Psychish-Gerichtlich Medicin 1907; 64: 146-148.
4. Arima K, Nakamura M, Sunohara N, Nishio T, Ogawa M, Hirai S, Kawai M, Ikeda K. Immunohistochemical and ultrastructural characterisation of neuritic clusters around ghost tangles in the hippocampal formation in progressive supranuclear palsy. Acta Neuropathol 1999; 97: 565-576.
5. Armstrong RA. Correlations between the morphology of diffuse and primitive β-amyloid (Aβ) deposits and the frequency of associated cells in Down’s syndrome. Neuropath Appl Neurobiol 1996; 22: 527-530.
6. Armstrong RA. β-amyloid plaques: stages in life history or independent origin? Dement Geriatr Cogn Disord 1998; 9: 227-238.
7. Armstrong RA. Diffuse β-amyloid (Aβ) deposits and neurons: in situ secretion or diffusion of Aβ? Alz Rep 2001; 3: 289-294.
8. Armstrong RA. Plaques and tangles and the pathogenesis of Alzheimer’s disease. Folia Neuropathol 2006; 44: 1-11.
9. Armstrong RA. Classic β-amyloid deposits cluster around large diameter blood vessels rather than capillaries in sporadic
Alzheimer’s disease. Curr Neurovasc Res 2006; 3: 289-294.
10. Armstrong RA. Size frequency distributions of abnormal protein deposits in Alzheimer’s disease and variant Creuztfeldt-Jakob disease. Folia Neuropathol 2007; 45: 108-114.
11. Armstrong RA. Spatial correlations between β-amyloid (Aβ) deposits and blood vessels in familial Alzheimer’s disease. Folia Neuropathol 2008; 46: 241-248.
12. Armstrong RA. Clustering and periodicity of neurofibrillary tangles in the upper and lower cortical laminae in Alzheimer’s disease. Folia Neuropathol 2008; 46: 26-31.
13. Armstrong RA, Nochlin D, Bird TD. Neuropathological heterogeneity in Alzheimer’s disease: A study of 80 cases using principal components analysis. Neuropathol 2000; 1: 31-37.
14. Armstrong RA, Cairns NJ, Lantos PL. Are pathological lesions in neurodegenerative disorders the cause or the effect of the degeneration? Neuropathol 2002; 22: 114-127.
15. Armstrong RA, Cairns NJ, Ironside JW, Lantos PL. Size frequency distributions of prion protein (PrP) aggregates in variant Creutzfeldt-Jakob disease. J Neural Transm 2005; 112: 1565-1573.
16. Armstrong RA, Cairns NJ, Ironside JW. Size frequency distributions of the florid prion protein aggregates in variant Creutzfeldt-Jakob disease follow a power-law function. Neuro Sci 2006; 27: 104-109.
17. Armstrong RA, Lantos PL, Cairns NJ. What determines the molecular composition of abnormal protein aggregates in neurodegenerative disease? Neuropathol 2008; 28: 351-365.
18. Atwood CS, Obrenovitch ME, Liu T, Chan H, Perry G, Smith MA, Martins RN. Amyloid-beta: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-β. Brain Res Rev 2004; 43: 1-6.
19. Bahr BA, Abai B, Gall CM, Vanderklish PW, Hoffman KB, Lynch G. Induction of β-amyloid containing polypeptides in hippocampus: evidence for a concomitant loss of synaptic proteins and interactions with an excitotoxin. Exp Neurol 1994; 129: 81-94.
20. Banati RB, Gehrmann J, Czech C, Monning U, Jones LL, Konig G, Beyreuther K, Kreutzberg GW. Early and rapid de novo synthesis of Alzheimer βA4-amyloid precursor protein (APP) in activated microglia. Glia 1993; 9: 199-210.
21. Bancher C, Grundke-Iqbal I, Iqbal K, Fried VA, Smith HT,
Wisniewski HM. Abnormal phosphorylation of tau precedes ubiquitination in neurofibrillary pathology of Alzheimer’s disease. Brain Research 1991; 539: 11-18.
22. Bancher C, Lassman H, Breitschopf H, Jellinger KA. Mechanisms of cell death in Alzheimer’s disease. J Neural Transm 1997; 50 (Suppl.): 141-152.
23. Beeson JG, Shelton ER, Chan HW, Gage FH. Age and damage induced changes in amyloid precursor protein immunohistochemistry in the rat brain. J Comp Neurol 1994; 342: 69-77.
24. Benzing WC, Mufson EJ. Apolipoprotein E immunoreactivity within neurofibrillary tangles: relationship to tau and paired helical filaments in Alzheimer’s disease. Exp Neurol 1995; 132: 162-171.
25. Berkenbosch F, Refolo LM, Friedrich VL, Casper D, Blum M, Robakis NK. The Alzheimer’s amyloid precursor protein is produced by type 1 astrocytes in primary cultures of rat microglia.
J Neurosci Res 1990; 25: 431-440.
26. Cairns NJ, Lee VM-Y, Trojanowski JQ. The cytoskeleton in neurodegenerative disease. J Pathol 2004; 204: 438-449.
27. Carroll BJ. Ageing, stress and the brain. Endocrine Facets of Ageing. Novartis Foundation Symposium, 2002; 242: 26-36.
28. Chartier-Harlin M, Crawford F, Houlden H, Warren A, Hughes D, Fidani L, Goate A, Rossor M, Rocques P, Hardy J, Mullan M. Early onset Alzheimer’s disease caused by mutations at codon 717 of the β-amyloid precursor protein gene. Nature 1991; 353: 844-846.
29. Cummings BJ, Su JH, Cotman CW, White R, Russell MJ. β-amyloid accumulation in aged canine brain: a model of early plaque formation in Alzheimer’s disease. Neurobiol Aging 1993; 14: 547-560.
30. Delacourte A, Sergeant N, Champain D, Wattez A, Maurage CA, Lebert F, Pasquier F, David JP. Nonoverlapping but synergetic tau and amyloid precursor protein pathologies in sporadic
Alzheimer’s disease. Neurology 2002; 59: 398-407.
31. Delaere P, Duyckaerts C, He Y, Piette F, Hauw JJ. Subtypes and differential laminar distribution of β/A4 deposits in Alzheimer’s disease: relationship with the intellectual status of 26 cases. Acta Neuropathol 1991; 81: 328-335.
32. Desai PP, Ikonomovic MD, Abrahamson EE, Hamilton RL, Isanski BA, Hope CE, Klunk WE, DeKosky ST, Kamboh MI. Apolipoprotein D is a component of compact but not diffuse amyloid-beta plaques in Alzheimer’s disease temporal cortex. Neurobiol Dis 2005; 20: 574-582.
33. Dickson DW. Neuropathological differentiation of progressive supranuclear palsy and corticobasal degeneration. J Neurol 1999; 246 (Suppl. 2): 6-15.
34. Dickson DW. Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders. International Society for Neuropathology (ISN) Press, Basel, Switzerland, 2003.
35. Drouet B, Pincon-Raymond M, Chambaz J, Pillot T. Molecular basis of Alzheimer’s disease. Cell and Molec Life Sci 2000; 57: 705-715.
36. Duong T, Pommier EC, Scheibel AB. Immunodetection of the amyloid P component in Alzheimer’s disease. Acta Neuropathol 1989; 78: 429-437.
37. Dustin P, Brion JP, Flament-Durand J. What’s new in the pathology of the neuronal cytoskeleton: The significance of neurofibrillary tangles. Pathol Res Pract 1992; 188: 248-253.
38. Eikelenboom P, Zhan SS, van Gool WA, Allsop D. Inflammatory mechanisms in Alzheimer’s disease. Trends in Pharmacol Sci 1994; 15: 447-450.
39. Ferrer I, Freixas M, Blanco R, Carmona M, Puig B. Selective PrP-like protein, doppel immunoreactivity in dystrophic neurites of senile plaques in Alzheimer’s disease. Neuropathol Appl Neurobiol 2004; 30: 329-337.
40. Forman MS, Trojanowski JQ, Lee VM-Y. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nature Med 2004; 10: 1055-1063.
41. Francis YI, Stephanou A, Latchman DS. CREB-binding protein activation by presenilin 1 but not by its M146L mutant. Neuroreport 2006; 17: 917-921.
42. Fraser PE, Nguyen JT, Chin DT, Kirschner DA. Effects of sulfate ions on Alzheimer β/A4 peptide assemblies: Implications for amyloid fibril-proteoglycan interactions. J Neurochem 1992; 59: 1531-1540.
43. Gertz HJ, Kruger H, Patt S, Cervos-Navarro J. Tangle-bearing neurons show more extensive dendritic trees than tangle-free neurons in area CA1 of the hippocampus in Alzheimer’s disease. Brain Res 1991; 548: 260-266.
44. Glenner GG, Wong CW. Alzheimer’s disease and Down’s syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 1984; 122: 1131-1135.
45. Goate R, Chartier-Harlin M, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irving N, James L, Mant R, Newton P, Rooke K, Roques P, Talbot C, Pericak-Vance M, Roses A, Williamson R, Rossor M, Owen M, Hardy J. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature 1991; 349: 704-706.
46. Goate AM. Monogenetic determinants of Alzheimer’s disease: Amyloid precursor protein mutations. Cell and Mole Life Sciences 1998; 54: 897-901.
47. Greenberg BD. The COOH-terminus of the Alzheimer amyloid Aβ peptide: Differences in length influence the process of amyloid deposition in Alzheimer brain, and tell us something about relationships among parenchymal and vessel-asssociated amyloid deposits. Amyloid 1995; 21: 195-203.
48. Haga S, Ikeda K, Sato M, Ishii T. Synthetic Alzheimer amyloid β/A4 peptides enhance production of complement C3 component by cultured microglia cells. Brain Res 1993; 601: 88-94.
49. Hainfellner JA, Wanschitz J, Jellinger K, Liberski PP, Gullotta F, Budka H. Coexistence of Alzheimer type neuropathology in Creutzfeldt-Jakob disease. Acta Neuropathol 1998; 96: 116-122.
50. Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science 1992; 256: 184-185.
51. Haupt M, Kurz A, Pollman S, Romero B. Comparison of the severity of neuropathological changes in familial and sporadic Alzheimer’s disease. J Neurol 1992; 239: 248-250.
52. Hoenicka J. Genes in Alzheimer’s disease. Revista de Neurolgia 2006; 42: 302-305.
53. Itagaki S, Akiyama H, Saito H, McGeer PL. Ultrastructural localization of complement membrane attack complex (MAC)-like immunoreactivity in brains of patients with Alzheimer’s disease. Brain Res 1994; 645: 78-84.
54. Jellinger KA, Bancher C. Neuropathology of Alzheimer’s disease: a critical update. J Neural Transm 1998; 54: 77-95.
55. Kalaria RN, Bhatti SU, Perry G, Lust WD. The amyloid precursor protein in ischaemic brain injury and chronic hypoperfusion. Proc 7th Inter Study Group Pharm Mem Dis Assoc Aging 1993; 291-294.
56. Khatchaturian ZS Diagnosis of Alzheimer’s disease. Arch Neurol 1985; 42: 1097-1105.
57. Kim JR, Muresan A, Lee KY, Murphy RM. Urea modulation of beta-amyloid fibril growth: Experimental studies and kinetic models. Protein Sci 2004; 13: 2888-2898.
58. Kimura M, Arai H, Takahashi T, Iwamoto N. Amyloid-P component like immunoreactivity in β/A4-immunoreactive deposits in Alzheimer-type dementia brains. J Neurol 1994; 241: 170-174.
59. Kowall NW, Beal MF. Cortical somatostatin, neuropeptide Y, and NADPH daiphorase neurons: normal anatomy and alterations in Alzheimer’s disease. Ann Neurol 1988; 23: 105-114.
60. Krzanowski JJ. Microglia and immune activation in Alzheimer’s disease. J Flor MA 1993; 80: 267-270.
61. Lasmann H. Patterns of synaptic and nerve cell pathology in Alzheimer’s disease. Beh Brain Res 1996; 78: 9-14.
62. Lemere CA, Blusztajn JK, Yamaguchi H, Wisniewski T, Saido TC, Selkoe DJ. Sequence of deposition of heterogeneous amyloid β-peptides and apolipoprotein E in Down’s syndrome: implications for initial events in amyloid plaque formation. Neurobiol Dis 1996; 3: 16-32.
63. Levy-Lahad E, Wasco W, Poorkaj P, Romano D, Oshima J, Pettingell W, Yu C, Jondro P, Schmidt S, Wang K, Crowley A, Fu Y,
Guenette S, Galas D, Nemens E, Wijsman E, Bird T, Schellenberg G, Tanzi R. Candidate gene for chromosome 1 familial Alzheimer’s disease locus. Science 1995; 269: 973-977.
64. Ma Y, Yee A, Brewer B, Das S, Potter H. Amyloid-associated proteins α1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments. Nature 1994; 372: 92-94.
65. Mann DMA, Younis N, Jones D, Stoddart RW. The time course of pathological events in Down’s syndrome with particular reference to the involvement of microglial cells and deposits of
b/A4. Neurodegen 1992; 1: 201-215.
66. Maruyama K, Kawamura Y, Asada H, Ishiura S, Obata K. Cleavage at the N-terminal site of Alzheimer amyloid β/A4 protein is essential for its secretion. Biochem Biophys Res Comms 1994; 202: 1517-1523.
67. Miller DL, Papayannopoulos IA, Styles J, Bobin SA, Lin YY, Biemann K, Igbal K. Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer’s disease. Arch Biochem Biophys 1993; 301: 41-52.
68. Mirra S, Heyman A, McKeel D, Sumi S, Crain B, Brownlee L, Vogel F, Hughes J, van Belle G, Berg L. The consortium to establish a registry for Alzheimer’s disease (CERAD). II. Standardisation of the neuropathological assessment of Alzheimer’s disease. Neurol 1991; 41: 479-486.
69. Mochizuki A, Peterson JW, Mufson EJ, Trapp BD. Amyloid load and neural elements in Alzheimer’s disease and nondemented individuals with high amyloid plaque density. Exp Neurol 1996; 142: 89-102.
70. Morris HR, Baker M, Yasojima K, Houlden H, Khan MN, Wood NW, Hardy J, Grossman M, Trojanowski J, Revesz T, Bigio EH, Bergeron C, Janssen JC, McGeer PL, Rossor MW, Lees AJ, Lantos PL, Hutton M. Analysis of tau haplotypes in Pick’s disease. Neurol 2002; 59: 443-445.
71. Mullan M, Crawford F. Genetic and molecular advances in Alzheimer’s disease. TINS 1993; 16: 398-403.
72. Munoz DG. Chromogranin A-like immunoreactive neuritis are major constituents of senile plaques. Lab Inv 1991; 64: 826-832.
73. Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer’s disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res 1991; 541: 163-166.
74. Newell KL, Boyer P, Gomez-Tortosa E, Hobbs W, Hedley-Whyte ET, Vonsattel JP, Hyman BT. Alpha-synuclein immunoreactivity is present in axonal swellings in neuroaxonal dystrophy and acute traumatic brain injury. J Neuropath Exp Neurol 1999; 58: 1263-1268.
75. Nochlin D, Van Belle G, Bird TD, Sumi SM. Comparison of the severity of neuropathological changes in familial and sporadic Alzheimer’s disease. Alz Dis Assoc Dis 1993; 7: 212-222.
76. Octave JN. The amyloid peptide precursor in Alzheimer’s disease. Acta Neurol Belg 1995; 95: 197-209.
77. Perry G. Neuritic plaques in Alzheimer’s disease originate from neurofibrillary tangles. Med Hypoth 1993; 40: 257-258.
78. Perry G, Siedlak SL, Richey P, Richey P, Kawai M, Cras P, Kalaria R, Galloway P, Scardina JM, Cordell B, Greenberg BD, Ledbetter SR, Gambetti P. Association of heparan sulfate proteoglycan with the neurofibrillary tangles of Alzheimer’s disease. J Neurol 1991; 11: 3679-3683.
79. Podlisny MB, Tolan DR, Selkoe DJ. Homology of amyloid beta protein precursor in monkey and human supports a primate model for beta amyloidosis in Alzheimer’s disease. Am J Pathol 1991; 138: 1423-1433.
80. Rangon CM, Haik S, Faucheux BA, Metz-Boutique MH, Fierville F, Fuchs JP, Hauw JJ, Aunis D. Different chromogranin immunoreactivity between prion and A β amyloid plaque. Neuro Report 2003; 14: 755-758.
81. Regland B, Gottfries CG. The role of amyloid β-protein in Alzheimer’s disease. Lancet 1992; 340: 467-469.
82. Roher AE, Lowenson JD, Clarke S. Wolkow W, Wang R, Cotter RJ, Reardon IM, Zurcherneely HA, Heinrikson RL, Ball MJ, Greenberg BD. Structural alterations in the peptide backbone of β-amyloid core protein may account for its deposition and stability in Alzheimer’s disease. J Biol Chem 1993; 268: 3072-3073.
83. Schmidt ML, Lee VMY, Trojanowski JQ. Comparative epitope analysis of neuronal cytoskeletal proteins in Alzheimer’s disease senile plaque neurites and neuropil threads. Lab Invest 1991; 64: 352-357.
84. Shalit F, Sredin B, Stern L, Kott E, Huberman M. Elevated interleukin-6 secretion levels by mononuclear cells of Alzheimer’s patients. Neurosci Lett 1994; 174: 130-132.
85. Sherrington R, Rogaev E, Liang Y, Rogaeva E, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, Tsuda T, Mar L, Foncin J, Bruni A, Moulese M, Sorbi S, Rainero I, Pinessi L, Nee L, Chumakov I, Pollen D, Brookes A, Sauseau P, Polinski R, Wasco R,
Dasilva H, Haines J, Pericak-Vance M, Tanzi R, Roses A, Fraser P,
Rommens J, St George-Hyslop P. Cloning of a gene bearing missense mutations in early onset familial Alzheimer’s disease. Nature 1993; 375: 754-760.
86. Smith MA, Kalaria RN, Perry G. α1-trypsin immunoreactivity in Alzheimer’s disease. Biochem Biophys Res Communs 1993; 193: 579-584.
87. Smith MA, Taneda S, Richey PL, Miyata S, Yan SD, Stern D, Sayre LM, Monnier VM, Perry G. Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc Natl Acad Sci USA 1994; 91: 5710-5714.
88. Steiner H, Capell A, Leimer U, Haass C. Genes and mechanisms involved in beta-amyloid generation and Alzheimer’s disease. Eur Arch Psych and Clin Neurol 1999; 249: 266-270.
89. Stephenson DT, Rash K, Clemens JA. Amyloid precursor protein accumulates in regions of neurodegeneration following focal cerebral ischaemia in the rat. Brain Res 1992; 593: 128-135.
90. Strittmatter W, Wiesgraber K, Huang D, Dong L, Salvesan G, Pericak-Vance M, Schmachel D, Saunders A, Goldgaber D, Roses A.
Binding of human apolipoprotein E to synthetic amyloid-β peptide: isoform specific effects and implications for late-onset Alzheimer’s disease. Proc Natl Acad Sci USA 1993; 90: 8098-8102.
91. Struble RG, Powers RE, Casanova MF, Kitt CA, Brown EC, Price DL. Neuropeptidergic systems in plaques of Alzheimer’s disease.
J Neuropath Exp Neurol 1987; 46: 567-584.
92. Styczyñska M, Strosznajder JB, Religa D, Chodakowska-¯ebrowska M, Pfeffer A, Gabrylewicz T, Czapski GA, Kobryœ M, Karciauskas G, Barcikowska M. Association between genetic and environmental factors and the risk of Alzheimer’s disease. Folia Neuropathol 2008; 46: 249-254.
93. Sudoh S, Kawamura Y, Sato K, Wang R, Saido TC, Oyama F, Sakaki Y, Komano H, Yanagisawa K. Presenilin-1 mutations linked to FAD increase the intracellular levels of amyloid beta protein 1-42 and its n-terminally truncated variant(s) which are generated at distinct sites. J Neurochem 1998; 71: 1535-1543.
94. Swerdlow RH, Khan SM. A “mitochondrial cascade hypothesis” for sporadic Alzheimer’s disease. Med Hypoth 2004; 63: 8-20.
95. Tabaton M, Cammarata S, Mancardi G, Manetto V, Autilio-Gambetti L, Perry G, Gambetti P. Ultrastructural localisation of β tau and ubiquitin epitopes in extracellular neurofibrillary tangles. Proc Natl Acad Sci 1991; 88: 2098-2102.
96. Togo T, Akiyama H, Iseki E, Uchikado H, Kondo H, Ikeda K, Tsuchiya K, de Silva R, Lees A, Kosaka K. Immunohistochemical study of tau accumulation in early stages of Alzheimer-type neurofibrillary lesions. Acta Neuropathol 2004; 107: 504-508.
97. Torack RM, Miller JW. Immunoreactive changes resulting from dopaminergic denervation of the dentate gyrus of the rat hippocampal formation. Neurosci Lett 1994; 169: 9-12.
98. Uchihara T, Duyckaerts C, Lazarini F, Mokhtari K, Seilhean D, Amouyel P, Hauw JJ. Inconstant apolipoprotein (Apo E) - like immunoreactivity in amyloid beta deposits: relationship with Apo E genotype in aging brain and Alzheimer’s disease. Acta Neuropathol 1996; 92: 180-185.
99. Van Gool D, Destrooper B de, Van Leuven F, Triau E, Dom R. α2-macroglobulin expression in neuritic-type plaques in patients with Alzheimer’s disease. Neurobiol Aging 1993; 14: 233-237.
100. Verga L, Frangione B, Tagliavini F, Giaccone G, Migheli A, Bugiani O. Alzheimer’s and Down’s patients: cerebral preamyloid deposits differ ultrastructurally and histochemically from the amyloid of senile plaques. Neurosci Lett 1989; 105: 294-299.
101. Wallace WC, Ahlers ST, Gotlib J, Bragin V, Sugar J, Gluck R, Shea PA, Davis KL, Haroutunian V. Amyloid precursor protein in the cerebral cortex is rapidly and persistently induced by loss of subcortical innervation. Proc Natl Acad Sci USA 1993; 90: 8712-8716.
102. Wisniewski HM, Merz PA, Iqbal K. Ultrastructure of paired helical filaments of Alzheimer’s neurofibrillary tangle. J Neuropath Exp Neurol 1984; 43: 643-656.
103. Wisniewski T, Ghiso J, Frangione B. Alzheimer’s disease and soluble Aβ. Neurobiol Aging 1994; 15: 143-152.
104. Yamaguchi H, Nakazato Y, Shoji M, Okamoto K, Ihara Y, Morimatsu M, Hirai S. Secondary deposition of beta amyloid within extracellular tangles in Alzheimer-type dementia. Am J Pathol 1991; 138: 699-705.
105. Yamaguchi H, Ishiguro K, Sugihara S, Nakazato Y, Kawarabayashi T, Sun XY. Presence of apolipoprotein e on extracellular neurofibrillary tangles and on meningeal blood vessels precedes the Alzheimer β-amyloid deposition. Acta Neuropathol 1994; 88: 413-419.
106. Zatti G, Burgo A, Giacomello M, Barbiero L, Ghidoni R, Sinigaglia C, Florean C, Bagnoli S, Binetti G, Sorbi S, Pizzo P, Fasolata C. Presenilin mutations linked to familial Alzheimer’s disease reduce endoplasmic reticulum and Golgi apparatues calcium levels. Cell Calcium 2006; 39: 539-550.
Copyright: © 2009 Mossakowski Medical Research Centre Polish Academy of Sciences and the Polish Association of Neuropathologists. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
pod redakcją Barbary Steinborn
Liczba stron 224
prof. dr hab. n. med. Joanna Hauser, dr n. med. Monika Dmitrzak-Węglarz
Liczba stron 168
Jean-François Etter, Gérard Mathern
Format: 125x197 mm
Liczba stron: 208
Tłumacz: Aneta Szaraniec
Redakcja merytoryczna: dr psychiatrii FILIP RYBAKOWSKI
Liczba stron: 352
Oprawa: miękka ze skrzydełkami